% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lepenies:282542,
author = {Lepenies, Laura K. and Seidling, Hanna M. and Pabst,
Alexander and Luppa, Melanie and Döhring, Juliane and
Williamson, Martin and Frese, Thomas and Gensichen, Jochen
and Hoffmann, Wolfgang and Kaduszkiewicz, Hanna and König,
Hans-Helmut and Thyrian, Jochen René and Wiese, Birgitt and
Riedel-Heller, Steffi G. and Czock, David},
title = {{D}eprescribing drugs with anticholinergic effects in older
patients with increased risk of dementia in the
multicomponent intervention study {A}ge{W}ell.de},
journal = {British journal of clinical pharmacology},
volume = {91},
number = {12},
issn = {0306-5251},
address = {Oxford},
publisher = {Wiley-Blackwell},
reportid = {DZNE-2025-01305},
pages = {3489 - 3500},
year = {2025},
abstract = {AimDrugs with anticholinergic effects are often considered
as potentially inappropriate medications, especially for
older patients, and deprescribing such drugs may improve
cognitive function. The aim was to investigate the
effectiveness of counselling on drug risks as part of a
multimodal intervention to prevent cognitive
decline.MethodsThe AgeWell.de study, a multi-centre,
cluster-randomized controlled study, was conducted in 123
German general practices between June 2018 and January 2022.
The study included a multicomponent intervention programme
for patients at increased risk of dementia, delivered over a
2-year period. As part of the medication optimisation
intervention, patient data and medication records were
screened to identify medication risks and provide
recommendations to general practitioners.ResultsIn total,
808 patients with complete data were included in the present
analysis (intervention group = 374, control
group = 434). At baseline, 132 $(16.8\%)$ patients had
at least one anticholinergic prescription. After 2 years,
approximately one-third of these patients no longer received
drugs with anticholinergic effects. There were no
significant differences between the intervention and control
groups, with $67.6\%$ and $72.1\%,$ respectively, continuing
to take drugs with anticholinergic effects (P = 0.57).
Patients reported anticholinergic symptoms more frequently
when taking any medication $(5.0\%$ vs $33.8\%),$ and even
more so when taking drugs with anticholinergic effects
$(56.1\%).$ Deprescribing of all drugs with anticholinergic
effects was non-significantly higher in patients who
reported at least one anticholinergic symptom compared to
patients without any anticholinergic symptoms $(58.6\%$ vs
$54.1\%).ConclusionThe$ medication optimisation intervention
did not entail significant differences in anticholinergic
deprescribing between the groups.},
cin = {AG Thyrian / AG Hoffmann},
ddc = {610},
cid = {I:(DE-2719)1510800 / I:(DE-2719)1510600},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
doi = {10.1002/bcp.70194},
url = {https://pub.dzne.de/record/282542},
}